Simplify Asset Management Inc. Buys Shares of 37,742 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Simplify Asset Management Inc. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,742 shares of the company’s stock, valued at approximately $711,000. Simplify Asset Management Inc. owned about 0.08% of Pacira BioSciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in PCRX. BNP Paribas Financial Markets boosted its holdings in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares during the last quarter. Verition Fund Management LLC bought a new position in Pacira BioSciences in the third quarter worth approximately $493,000. Segall Bryant & Hamill LLC purchased a new position in shares of Pacira BioSciences during the 3rd quarter worth $483,000. Centiva Capital LP purchased a new position in shares of Pacira BioSciences during the 3rd quarter worth $398,000. Finally, State Street Corp grew its position in shares of Pacira BioSciences by 5.8% during the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after acquiring an additional 110,162 shares during the period. 99.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PCRX shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright boosted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barclays raised their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Finally, Needham & Company LLC upped their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Trading Up 1.3 %

Pacira BioSciences stock opened at $24.14 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The firm’s 50 day moving average price is $24.44 and its 200-day moving average price is $19.58. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.67. The stock has a market cap of $1.12 billion, a P/E ratio of -11.89 and a beta of 0.86.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.